Abstract
Background: Lung cancer is the leading cause of cancer-related death in Australia, accounting for 18.7% in 2017; and an estimated incidence of 43 cases per 100,000 persons in 2013, making it the 5th most common cancer. Many genetic abnormalities are essential in driving tumorigenesis. Anaplastic lymphoma kinase (ALK) gene rearrangement is responsible for 3–7% of all non-small cell lung cancers (NSCLC); which are responsive to tyrosine kinase inhibitors. Therefore, detection of such genetic abnormalities has become mainstay practice in the diagnostic workup for lung cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.